<DOC>
	<DOCNO>NCT02722369</DOCNO>
	<brief_summary>To determine whether combination gemcitabine/carboplatin hydroxychloroquine ( HCQ ) associate improved clinical outcome ( progression free overall survival ) compare chemotherapy alone patient small cell lung cancer ( SCLC )</brief_summary>
	<brief_title>STUDY 15 - Comparing Gemcitabine/Carboplatin Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description>This multicentre , randomise , phase II trial aim compare combination hydroxychloroquine gemcitabine/carboplatin versus standard carboplatin/etoposide chemotherapy , first line treat patient stage IV disease . The standard first line chemotherapy treatment remain platinum-based chemotherapy unchanged 20 year . Novel active treatment approach urgently need improve survival SCLC . Patients randomise one two treatment arm ; carboplatin/etoposide gemcitabine/carboplatin/hydroxychloroquine .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm SCLC Stage IV disease Performance status ECOG 02 Life expectancy &gt; 8 week Age 18 Willing able give inform consent Patient consider able tolerate chemotherapy Adequate renal function define GFR ≥50mL/min measure EDTA C &amp; G Adequate bone marrow reserve : Absolute neutrophil count ≥1.5 x 109/L , haemoglobin ≥90 g/L , platelet count ≥100 x 109/L Negative pregnancy test WCBP Effective contraception mandatory patient reproductive potential At least one site measurable disease ( target lesion ) RECIST 1.1 evaluation Able swallow medication Mixed cell histology ( i.e . NSCLC SCLC ) Prior macular degeneration diabetic retinopathy History glaucoma Patients abnormal LFTs ( ALP , ALT/AST* ) ≥3 x ULN ( ≥5 x ULN patient liver metastasis ) Patients abnormal bilirubin level ≥1.5 x ULN Prior treatment disease e.g . chemotherapy , surgery , radiotherapy ( expect palliative radiotherapy bone metastasis ) Documented side effect chloroquine related agent Treatment chloroquine relate agent within last year prior randomisation Glucose6 phosphate dehydrogenase ( G6PD ) deficiency Concurrent psoriasis unless disease well control patient care specialist disorder agree monitor exacerbation Evidence significant medical condition laboratory finding , opinion investigator , make undesirable patient participate trial Previous medical history prolong QT interval A history prior malignant tumour , unless patient without evidence disease least 3 year tumour nonmelanoma skin tumour early cervical cancer Patients symptomatic brain metastasis Women breastfeed Concurrent cytochrome P450 enzymeinducing anticonvulsant drug e.g . phenytoin , carbamazepine , phenobarbital , primidone oxcarbazepine Patients unable digoxin level regularly monitor ALT AST perform need record</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>